Mycophenolate mofetil and atherosclerosis - Results of animal and human studies

被引：22

作者：

Gibson, William Thomas ^{[1
]}

Hayden, Michael Reuben ^{[1
]}

机构：

[1] Univ British Columbia, Child & Family Res Inst, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada

来源：

AUTOIMMUNITY, PT B: NOVEL APPLICATIONS OF BASIC RESEARCH | 2007年 / 1110卷

关键词：

atherosclerosis; coronary allograft vasculopathy; immunosuppressants; mycophenolate mofetil; mycophenolic acid; transplantation;

D O I：

10.1196/annals.1423.023

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The immunosuppressive agent mycophenolate mofetil (MMF) has beneficial effects in cardiac transplant patients beyond the suppression of tissue rejection. Patients with regimens containing MMF experience diminished intimal thickening and cardiac allograft vasculopathy compared to patients treated with azathioprine. Studies have shown that diet-induced atherosclerosis (a related vasculopathy) is a chronic inflammatory process, and so MMF has also been used to reduce atherosclerosis in a rabbit model of hyperlipidemia. These data hold out the intriguing possibility that MMF might be a viable primary or secondary preventive agent in people at significant risk for atherosclerosis.

引用

页码：209 / 221

页数：13

共 50 条

[11] Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes [J].